Pulse Biosciences has a Cash Ratio of 6.61. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Pulse Biosciences's Cash Ratio or its related term are showing as below:
PLSE'
s Cash Ratio Range Over the Past 10 Years
Min: 2.7 Med: 8.42 Max: 42.48
Current: 6.61
During the past 10 years, Pulse Biosciences's highest Cash Ratio was 42.48. The lowest was 2.70. And the median was 8.42.
PLSE's Cash Ratio is ranked better than 88.43% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 1.25
vs PLSE: 6.61
Pulse Biosciences Cash Ratio Historical Data
The historical data trend for Pulse Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pulse Biosciences's Cash Ratio
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's Cash Ratio falls into.
Pulse Biosciences Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Pulse Biosciences's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (NAS:PLSE) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Pulse Biosciences Cash Ratio Related Terms
Thank you for viewing the detailed overview of Pulse Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Pulse Biosciences (Pulse Biosciences) Business Description
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PLSE has been successfully added to your 